Apr. 2005
history_yamanouchi_fujisawa

Astellas Pharma Inc. (Astellas) was established by merging the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd.

Apr. 2006
optimization_of_resource_allocation
Astellas sold Zephama, operating in the over-the-counter drug business, to Daiichi Sankyo Co., Ltd. in Japan to concentrate Astellas' managerial resources on its ethical drug business.
Oct. 2007
geninax
launch_of_new_products

Astellas launched Geninax®, an oral new-type quinololone antibacterial agent, in Japan.

Dec. 2007
building_a_platform_to_support_growth
Astellas acquired Agensys, Inc., a biotechnology company specialized in therapeutic antibody research and development in cancer in the U.S.
June 2010
building_a_platform_to_support_growth
Astellas acquired OSI Pharmaceuticals, Inc., a biotechnology company in the U.S. to create an oncology platform.
July 2011
launch_of_new_products

Astellas launched Betanis® in Japan for the treatment of overactive bladder (OAB).

Nov. 2011
initiatives_to_support_society_and_companys_sustainable_growth

Astellas signed United Nations Global Compact.

Mar. 2012
ireland_plants
initiatives_to_support_society_and_companys_sustainable_growth

Astellas launched a wind turbine power generation station and a woodchip biomass boiler in the Kerry Plant in Ireland.

July 2012
initiatives_to_support_society_and_companys_sustainable_growth

Astellas participated in the new public-private partnership to develop a treatment for schistosomiasis-infected preschool children.

Sept. 2012
launch_of_new_products

Astellas launched XTANDI® in the U.S. for the treatment of metastatic castration-resistant prostate cancer.

Oct. 2012
launch_of_new_products

Astellas launched Gonax® in Japan for the treatment of prostate cancer.

Oct. 2012
initiatives_to_support_society_and_companys_sustainable_growth

Astellas entered collaborative new drug discovery research with the National Institute of Advanced Industrial Science and Technology (AIST) for neglected tropical diseases caused by protozoan parasites.

Oct. 2012
launch_of_new_products

Astellas launched MYRBETRIQ® in the U.S. for the treatment of OAB.

Mar. 2013
cimzia
launch_of_new_products

Astellas and UCB Japan launched Cimzia® in Japan for the treatment of adult patients with rheumatoid arthritis.

Apr. 2013
initiatives_to_support_society_and_companys_sustainable_growth

Astellas announced participation in Global Health Innovative Technology Fund (GHIT Fund).

May 2013
astellas_and_amgen
building_a_platform_to_support_growth

Astellas and Amgen concluded an agreement for established alliance innovative joint venture, Astellas Amgen Biopharma in Japan.

Apr. 2014
suglat
launch_of_new_products

Astellas launched Suglat® in Japan for the treatment of type 2 diabetes.

May 2014
initiatives_to_support_society_and_companys_sustainable_growth

Astellas funded a €1.5 million groundbreaking programme to tackle obstetric fistula in Kenya.

May 2014
xtandi
launch_of_new_products

Astellas launched XTANDI® in Japan for the treatment of prostate cancer.

Feb. 2016
ocata
building_a_platform_to_support_growth

Astellas acquired Ocata Therapeutics, Inc., a biotechnology company in the U.S. to enable Astellas to establish a presence in ophthalmology and a leading position in cell theapy.

Apr. 2016
repatha
launch_of_new_products

Astellas launched Repatha® in Japan for the treatment of high cholesterol.

Oct. 2016
initiatives_to_support_society_and_companys_sustainable_growth
Astellas and World Anti-Doping Agency announced global initiative to prevent misuse and abuse of medicines for doping in sports.
Dec. 2016
ganymed
building_a_platform_to_support_growth

Astellas acquired Ganymed Pharmaceticals AG, a biopharmaceutical company, in Germany to further expand Astellas' oncology presence by adding anti-body program, zolbetuximab.

Jan. 2017
initiatives_to_support_society_and_companys_sustainable_growth

Astellas participated in Access Accelerated, a global initiative aimed at improving access to non-communicable diseases prevention, diagonosis and treatment.

Mar. 2017
linzess
launch_of_new_products

Astellas launched LINZESS® in Japan for the treatment of irritable bowel syndrome with conspitation.

May 2017
ogeda
building_a_platform_to_support_growth

Astellas acquired Ogeda SA, a drug discovery company, in Belgium to expand Astellas' pipeline by adding a selective NK3 receptor atagonist, fezolinetant.

Oct. 2017
initiatives_to_support_society_and_companys_sustainable_growth
Astellas entered into a new collaborative research agreement with TB Alliance to discover anti-tuberculosis drugs.
Oct. 2017
initiatives_to_support_society_and_companys_sustainable_growth

Astellas entered into a screening collaboration agreement with Medicines for Malaria Venbure to discover antimalarial drugs.

Jan. 2018
mitobridge
building_a_platform_to_support_growth

Astellas acquired Mitobridge, Inc., a bio-venture company in the U.S. to accelerate Astellas' research and development in diseases associated with mitochondrial dysfunctions.

Feb. 2018
universalcells
building_a_platform_to_support_growth

Astellas acquired Universal Cells, Inc., a bio-venture company which has ability to produce pluripotent stem cells that have lower immunological rejections.

Mar. 2018
initiatives_to_support_society_and_companys_sustainable_growth

Astellas participated in Neglected Tropical Diseases Drug Discovery Booster Consortium with DNDi and Seven Other Pharmaceutical Companies.

Aug. 2018
quethera
building_a_platform_to_support_growth

Astellas acquired Quethera, a gene theraphy company in the U.K. to further Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma.

Sept. 2018
dafclir
launch_of_new_products

Astellas launched Dafclir® in Japan for the treatment of infectious enteritis caused by Clostridium difficile.

Oct. 2018

Astellas and BANDAI NAMCO Entertainment Inc. concluded an agreement for joint development of application for smartphone exercise support application.

Nov. 2018
initiatives_to_support_society_and_companys_sustainable_growth

Science Based Targets Initiative approved Astellas’ greenhouse gas reduction plan.

Nov. 2018
blincyto
launch_of_new_products

Astellas launched BLINCYTO® in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.

Nov. 2018
initiatives_to_support_society_and_companys_sustainable_growth

Astellas launched the Astellas Global Health Foundation to support improving access to health for underserved populations.

Dec. 2018
xospata
launch_of_new_products

Astellas launched XOSPATA® in Japan to provide a therapeutic option for the treatment of Acute Myeloid Leukemia.

Dec. 2018
potenza
building_a_platform_to_support_growth

Astellas acquired Potenza Therapeutics Inc. in the U.S. to add clinical stage novel immuno-oncology programs to Astellas' oncology pipeline.

Mar. 2019
evenity
launch_of_new_products

Astellas launched EVENITY® in Japan for the treatment of osteoporosis.

July 2019
smyraf
launch_of_new_products
Astellas launched Smyraf® in Japan for the treatment of rheumatoid arthritis in patients.
Nov. 2019
evrenzo
launch_of_new_products

Astellas launched Evrenzo® in Japan for the treatment of renal anemia in patients on dialysis.

Nov. 2019
Astellas entered into strategic alliance for digital therapeutics with Welldoc, Inc., a digital health company.
Dec. 2019
xyphos
building_a_platform_to_support_growth

Astellas acquired Xyphos Biosciences, Inc., a biotechnology company in the U.S. to accelerate next-generation cancer immunotherapy.

Dec. 2019
launch_of_new_products

Astellas lauched PADCEV® in the U.S. for the treatment of urothelial cancer.

Jan. 2020
audentes
building_a_platform_to_support_growth

Astellas acquired Audentes Therapeutics, Inc., a biotechnology company in the U.S. to complement capabilities and resources of Astellas for creating an industry-leading gene therapy company.

Apr. 2020
audentes
building_a_platform_to_support_growth

Astellas acquired Nanna Therapeutics Limited, in the U.K. to accelerate Astellas' research in diseases associated with mitochondrial dysfunctions.

June 2020
Astellas, City of Yokohama, and Yokohama City University developed science-based exercise programs through industry-government-academia collaboration.
Sept. 2020

Astellas launched science-based fitness service, Fit-eNce®.

Oct. 2020

Astellas acquired iota Biosciences, Inc. in the U.S. to explore new biosensing and treatment measures using ultra-small implantable medical devices.

Dec. 2020
initiatives_to_support_society_and_companys_sustainable_growth

Astellas supported recommendations of Task Force on Climate-related Financial Disclosures (TCFD).

 

Icon Description:

launch_of_new_products

​Launch of New Products

building_a_platform_to_support_growth

Building a Platform to Support Growth

optimization_of_resource_allocation

Optimization of Resource Allocation

initiatives_to_support_society_and_companys_sustainable_growth

Initiatives to Support Society and Company's Sustainable Growth

rx_business

Rx+® Business​